Professor Chapman is Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris, France, affiliated to the Medical Faculty of the Pierre and Marie Curie University, Paris. In 2002, he was appointed to a Senior Clinical Investigatorship in the Paris Hospitals – Public Assistance Healthcare System, and was nominated as a Distinguished Fellow of the International Atherosclerosis Society in 2007.
John Chapman is a longstanding EAS member and has served on the Executive Committee of the European Atherosclerosis Society from 2001 to 2005. John Chapman is presently Associate European Editor of “Arteriosclerosis, Thrombosis and Vascular Biology” and “Pharmacology and Therapeutics”. He is Editorial Board member of “Atherosclerosis”, “ Future Lipidology”, and “Current Medical Research and Opinion”.
He received his B.Sc. (Hons) degree at the University of Aberdeen, Scotland, and his Ph.D. degree in Medical Biochemistry at the Middlesex Hospital Medical School, University of London. His postdoctoral training in Cardiovascular Lipidology was completed at the Cardiovascular Research Institute of the University of California Medical Center, San Francisco, CA, under the direction of Dr R.J. Havel.
From 1978 to 1982 he served as an Established Research Investigator at INSERM. He also trained in Biophysics with Dr D.M. Small at Boston University and in Cell Receptor Biology with Profs. Brown and Goldstein at Southwestern Medical School in Dallas. John Chapman was an Honorary Visiting Research Scientist at the Gladstone Foundation for Cardiovascular Disease in San Francisco(,1982-1985) where he studied the receptor-binding domains of apo B100 .
In recognition of his contributions to the field of “Plasma lipoproteins : Structure, Metabolism and Role in Atherothrombosis”, he was awarded the Doctor of Science degree by the University of London in 2002. The focal points of his research interests have been:
- The structure, metabolism, and biological activities of atherogenic apo.B-containing particle subspecies (VLDL, LDL and Lp(a)).
- The relationship of HDL particle heterogeneity to atheroprotective activity in normolipidemia and in atherogenic dyslipidemia.
- The role of CETP in the regulation of intravascular lipoprotein metabolism.
- The pharmacological modulation of lipoprotein metabolism in atherogenic dyslipidemias and metabolic disease.
- The role of monocyte-macrophages and foam cells in the inflammatory fragilisation and thrombogenicity of the atherosclerotic plaque
He was elected Vice- Chairman of the Gordon Conference on Atherosclerosis to be held in the USA for the year 2009, and Chairman of the same Conference for 2012 to be held in Europe.